Financial Performance - The company's operating revenue for the first quarter was RMB 499,355,000, representing a year-on-year increase of 6.98%[4] - Net profit attributable to shareholders was RMB 121,413,000, with a basic and diluted earnings per share of RMB 0.49[4] - Total revenue for Q1 2022 reached RMB 499,355 thousand, an increase of 6.3% compared to RMB 466,758 thousand in Q1 2021[22] - Operating profit for Q1 2022 was RMB 121,874 thousand, a significant recovery from a loss of RMB 16,190 thousand in Q1 2021[23] - Net profit for Q1 2022 was RMB 114,295 thousand, compared to a net loss of RMB 15,752 thousand in Q1 2021[23] - Basic earnings per share for Q1 2022 was RMB 0.49, recovering from a loss of RMB 0.06 per share in Q1 2021[24] Research and Development - Research and development expenses totaled RMB 159,416,000, a decrease of 40.91% compared to the previous year, accounting for 31.92% of operating revenue[4][7] - Research and development expenses for Q1 2022 were RMB 157,155 thousand, down from RMB 269,788 thousand in Q1 2021, a decrease of 41.7%[22] Assets and Liabilities - The total assets at the end of the reporting period were RMB 11,933,983,000, reflecting a 0.50% increase from the previous year[5] - The total liabilities as of March 31, 2022, amounted to RMB 3,353,777 thousand, slightly up from RMB 3,326,303 thousand as of December 31, 2021[20] - Total equity increased to RMB 8,580,206 thousand as of March 31, 2022, compared to RMB 8,547,884 thousand at the end of 2021[20] - Long-term borrowings rose significantly to RMB 155,000 thousand in Q1 2022 from RMB 40,000 thousand in Q4 2021, an increase of 287.5%[20] Cash Flow - The net cash flow from operating activities was negative at RMB (598,148,000), indicating a decrease in cash inflow compared to the same period last year[4][7] - Cash inflow from operating activities totaled 230,369,000, a decrease from 525,180,000 in the previous year[26] - Cash outflow from operating activities increased to 828,517,000, compared to 537,596,000 in the prior year[26] - Cash inflow from investment activities was 2,135,294,000, up from 304,765,000 year-over-year[27] - Net cash flow from investment activities was (894,010,000), compared to 8,094,000 in the prior year[27] - Cash inflow from financing activities was 517,416,000, compared to 251,535,000 in the previous year[27] - Net cash flow from financing activities was 22,723,000, down from 228,284,000 year-over-year[27] - The net increase in cash and cash equivalents was (1,481,585,000), compared to an increase of 232,336,000 in the prior year[28] - The ending balance of cash and cash equivalents was 3,973,871,000, down from 4,678,365,000 in the previous year[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,318[8] - The top shareholder, HKSCC Nominees Limited, held 39.63% of the shares[9] Strategic Initiatives - The company plans to continue its focus on the commercialization of its products, which has positively impacted net profit attributable to shareholders[7] - The company has engaged in strategic partnerships and investments, including the involvement of several venture capital firms as significant shareholders, indicating a collaborative approach to market expansion and innovation[11] Market Context - The global vaccination rate is expected to slow down, with increased competition in the COVID-19 vaccine market, which may lead to a decrease in supply prices and heightened demands for product safety and efficacy[14] - The company’s ongoing development of a new COVID-19 vaccine has received approval for sequential booster immunization in China as of February 2022, and it is currently undergoing the process to include the vaccine in the WHO's Emergency Use Listing[13]
康希诺生物(06185) - 2022 Q1 - 季度财报